What’s new at SeqOne?
New platform features, customer success stories, awards and other great news about SeqOne…. you’ll find it all here. Journalists, we have a dedicated page for you.
-
News17 March 2023
SeqOne Genomics appoints Hervé Pouzoullic as Chief Commercial Officer
A seasoned leader in the pharmaceutical and diagnostics industry, specialized in structuring international healthcare sales joins the team to accelerate international expansion Montpellier, March 14 [...]
-
News Press release
22 February 2023
SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors. SeqOne’s test simplifies the deployment of this test while [...]
-
News Platform features Press release Science
9 February 2023
SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
Montpellier, February 9th, 2023: SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving [...]
-
News Press release
21 October 2022
Michael Blum joins SeqOne Genomics to head the company’s Research and Development
Renowned specialist in healthcare data science, he will focus on developing A.I. driven genomic analysis solutions to facilitate personalised medicine in oncology and rare diseases [...]
-
Events News Press release
20 October 2022
SeqOne Genomics announces Portuguese distribution partnership
SeqOne has appointed ILC Instrumentos de Laboratório to distribute its genomic analysis software platform in Portugal, and to accelerate the availability of its advanced genomic [...]
-
News Press release18 May 2022
We are hiring a VP of Platform Sales
VP of Platform Sales: SeqOne is a well-funded company developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is [...]
-
Events News Press release
18 May 2022
SeqOne Genomics and Global Diagnostic Solutions Limited (GDS) extend their collaboration in MENA
The companies will participate at the Precision Med Expo Dubai 24th and 25th of May 2022 Montpellier, France – Dubai, May 18, 2022 - SeqOne Genomics, provider of [...]
-
Events News Publications6 May 2022
SeqOne posters at the ESHG: using ML and big data to improve variant interpretation
SeqOne will be at the ESHG show in Vienna in hall X4 booth 664. We will be presenting four posters high-lighting various projects by SeqOne's [...]
-
News Press release
4 February 2022
SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina
The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze [...]
-
News Press release
24 January 2022
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The funding will drive international deployment of the company’s next generation genomic analysis platform to enable personalized medicine in cancers as well as rare and [...]
-
News Press release
19 November 2021
SeqOne expands its commercial presence in Middle Eastern markets
Genomics analysis becomes more accessible in MENA region: a new era for genetic diagnostics Montpellier – November 16th 2021. SeqOne Genomics, a leader in the [...]
-
News Platform features
27 September 2021
SeqOne unlocks the power of Illumina’s TruSightTM Oncology 500
With the addition of the TSO500 pan-cancer NGS assay for genomic profiling of tumour samples, SeqOne now provides oncologists with the most comprehensive genomic data [...]
